Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editor's notes
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119174

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

M Müller, S Strand, H Hug, E M Heinemann, H Walczak, W J Hofmann, W Stremmel, P H Krammer, and P R Galle

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Müller, M. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Strand, S. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Hug, H. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Heinemann, E. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Walczak, H. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Hofmann, W. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Stremmel, W. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Krammer, P. in: JCI | PubMed | Google Scholar

University Hospital, Department of Internal Medicine IV, Heidelberg, Germany.

Find articles by Galle, P. in: JCI | PubMed | Google Scholar

Published February 1, 1997 - More info

Published in Volume 99, Issue 3 on February 1, 1997
J Clin Invest. 1997;99(3):403–413. https://doi.org/10.1172/JCI119174.
© 1997 The American Society for Clinical Investigation
Published February 1, 1997 - Version history
View PDF
Abstract

Chemotherapeutic drugs are cytotoxic by induction of apoptosis in drug-sensitive cells. We investigated the mechanism of bleomycin-induced cytotoxicity in hepatoma cells. At concentrations present in the sera of patients during therapy, bleomycin induced transient accumulation of nuclear wild-type (wt) p53 and upregulated expression of cell surface CD95 (APO-1/Fas) receptor in hepatoma cells carrying wt p53 (HepG2). Bleomycin did not increase CD95 in hepatoma cells with mutated p53 (Huh7) or in hepatoma cells which were p53-/- (Hep3B). In addition, sensitivity towards CD95-mediated apoptosis was also increased in wt p53 positive HepG2 cells. Microinjection of wt p53 cDNA into HepG2 cells had the same effect. In contrast, bleomycin did not enhance susceptibility towards CD95-mediated apoptosis in Huh7 and in Hep3B cells. Furthermore, bleomycin treatment of HepG2 cells increased CD95 ligand (CD95L) mRNA expression. Most notably, bleomycin-induced apoptosis in HepG2 cells was almost completely inhibited by antibodies which interfere with CD95 receptor/ligand interaction. These data suggest that apoptosis induced by bleomycin is mediated, at least in part, by p53-dependent stimulation of the CD95 receptor/ligand system. The same applies to other anti-cancer drugs such as cisplatin and methotrexate. These data may have major consequences for drug treatment of cancer and the explanation of drug sensitivity and resistance.

Version history
  • Version 1 (February 1, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts